Trials / Completed
CompletedNCT02332499
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 419 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
Detailed description
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Placebo | Placebo p.o. qd |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-08-18
- Completion
- 2019-03-01
- First posted
- 2015-01-06
- Last updated
- 2019-05-21
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02332499. Inclusion in this directory is not an endorsement.